Cancer Treatment Today » DLI. Donor Lymphocyte Infusion.Allogeneic Tranpslantation. Graft Versus Host Disease.Donor Lymphocyte INfusion. Realped. T-Cell leukemai. http://cancertreatmenttoday.org Knowledge is Power Thu, 26 Mar 2026 23:39:25 +0000 en-US hourly 1 DLI for T cell leukemia and lymphoma – pro http://cancertreatmenttoday.org/dli-for-t-cell-leukimias-and-lymphomas-pro/ http://cancertreatmenttoday.org/dli-for-t-cell-leukimias-and-lymphomas-pro/#comments Fri, 10 Jan 2014 16:27:04 +0000 M Levin, MD http://cancertreatmenttoday.org/?p=11808 Donor lymphocyte infusions are designed to awaken some degree of graft versus host reaction, which contains within it also the graft versus disease effect. It is a modality that can be used after allogeneic transplantation to treat relapse by “awakening” an immune response. . Almost all work on DLI was in B cell leukemias and lymphomas.  How it affects T cell malignancies is not well studied and most of what is known was in Adult T-Cell leukami/Lymphoma. Many questions remain. For example,  achieving hematologic remission with DLI is not an easy task, especially in patients with a high tumor burden and rapidly proliferating leukemic cells.. Cytoreductive therapy before DLI is thought to improve effectiveness of DLI. Unfortunately, which regimens to use for this cytoreduction has not been defined. How to induce and manage graft versus host reaction has not been defined. Even the very effectiveness of allogeneic transplantation in T-Cell Leukemias continues to be studied. To conclude,  DLI remains experimental for T Cell malignancies due to lack of reliable information on how to do it and how effective it is.

Hidehiro Itonag et al, Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience    Blood January 3, 2013 vol. 121 no. 1 219-225

Gabriel IH. Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides. Bone Marrow Transplant 2007;40(4):401-403.

Herbert KE, . Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34(6):521-525.

 

For Lay version see here

]]> http://cancertreatmenttoday.org/dli-for-t-cell-leukimias-and-lymphomas-pro/feed/ 0